B+
Bull case
25%
Probability
Target price
$2.40
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
OABI
OmniAbFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The bull case is that OmniAb’s 107 active partners, 407 active programs and growing set of later-stage partnered assets can gradually convert a low-revenue platform story into a milestone-and-royalty story, while OmniUltra and xPloration widen platform relevance and help sustain partner additions [#8-K-2026-03-04].
Posture
Defensive
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-10-30 · BMO.
What can break
2026 guidance still implies meaningful cash burn and a lower year-end cash balance.
Momentum
99
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.40 · Bull $2.40 · Bear $0.70Analysis 2026-04-15; returns require an exact persisted reference.
Earnings
2026-10-30 · BMO
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $8.21
Why
Momentum99 · Δ7d +0.2
Value41 · Δ7d -0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Next scheduled catalyst: earnings 2026-10-30 · BMO.
- • Value remains the lead driver in the composite, 7D delta -0.1.
Contradictions & invalidation
- • 2026 guidance still implies meaningful cash burn and a lower year-end cash balance.
- • Competition in antibody discovery and screening remains intense across transgenic platforms and related discovery technologies [#10-K-2026-03-04].
- • The bear case is that OmniAb remains dependent on partner-controlled development events, posted lower 2025 revenue, and guided to another year of material cash burn; if partner timelines slip or monetization from newer offerings stays modest, the stock can remain trapped in a low-conviction monitoring range with financing risk creeping higher [#8-K-2026-03-04].
Catalyst clock
2026-10-30 · BMO
H1 2026 partner readouts are the nearest sentiment test
Lead driver: Value · See fundamentals
Momentum
99
8% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
-0.3
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
0
45% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade F. Momentum 98.7 / Value 40.6 / Sentiment 0.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-15. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$1.40
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$0.70
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$677.52M
Beta
0.15
Shares Out
145.39M
P/E (TTM) · Derived
-8.2
P/S (TTM)
12.63
P/FCF (TTM) · Derived
-30.90
Rev YoY
+244.2%
EPS YoY
-69.6%
Gross Margin
+36.4%
Op Margin
-126.0%
Net Debt
-$33.69M
Current Ratio
4.80
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data